# Nature Medicine’s 2026 Medical AI Superintelligence Framework Signals What FDA Benchmarking Guidance Has Not Yet Addressed - The Clinical Trial Vanguard

*Источник: The Clinical Trial Vanguard*
*Дата: 2026-07-28*
*Язык: en*

<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxOMkdBNVUtanltTXZqOF9rTTAzb2kwQVFhc2d4b0thSmdtb09oVW9CY1JXY2g1UGJITzZBU1UxTktveXpWalNJVWdkRWlmelVKMnBEdW1XSXpMc2hhN2FaTjd0dXJwUk9IR0VnTXJmZ0xyYWZUbnJoaDU5VEY0eWZudXNhckhXSDhhZk02bW9NVndJdE5DWG81bWRLbHhZTTRGT0VGM09hajRCeUQ1WlVqUGVfbDBDSnRISEZJSm91bFI0OTRCZkR6UXhDNm1Ja0tFNUdZVVoyTnBOQlhmZ1hKNzRQTGRzSGk4cUhUWk9QN203ME9hamt0ZWpWT04?oc=5" target="_blank">Nature Medicine’s 2026 Medical AI Superintelligence Framework Signals What FDA Benchmarking Guidance Has Not Yet Addressed</a>&nbsp;&nbsp;<font color="#6f6f6f">The Clinical Trial Vanguard</font>

[Оригинал](https://www.clinicaltrialvanguard.com/opinion/nature-medicines-2026-medical-ai-superintelligence-framework-signals-what-fda-benchmarking-guidance-has-not-yet-addressed/)